Purchase one-time access:Academic and Personal
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block.Can J Cardiol. 2017; 33: 1736
- A beginner’s guide to permanent left bundle branch pacing.Heart Rhythm. 2019; 16: 1791-1796
- Left bundle branch pacing: a comprehensive review.J Cardiovasc Electrophysiol. 2020; 31: 2462-2473
- Left bundle branch area pacing for cardiac resynchronization therapy: results from the International LBBAP Collaborative Study Group.JACC Clin Electrophysiol. 2021; 7: 135-147
- Latency during left ventricular pacing from the lateral cardiac veins: a cause of ineffectual biventricular pacing.Pacing Clin Electrophysiol. 2006; 29: 574-581
- Mortality and morbidity in cardiac resynchronization patients: impact of lead position, paced left ventricular QRS morphology and other characteristics on long-term outcome.Europace. 2013; 15: 258-265
Vijayaraman P. Left bundle branch pacing optimized cardiac resynchronization therapy: a novel approach [published online ahead of print July 21, 2021]. JACC Clin Electrophysiol. https://doi.org/10.1016/j.jacep.2021.04.005.
- Deep septal deployment of a thin, lumenless pacing lead: a translational cadaver simulation study.Europace. 2020; 22: 156-161
- Fixation beats: a novel marker for reaching the left bundle branch area during deep septal lead implantation.Heart Rhythm. 2021; 18: 562-569
- Template beat: a novel marker for left bundle branch capture during physiological pacing.Circ Arrhythm Electrophysiol. 2021; 14e009677
- Reaching the left bundle branch pacing area within 36 heartbeats.Kardiol Pol. 2021; 79: 587-588
- ECG and pacing criteria for differentiating conduction system pacing from myocardial pacing.Arrhythm Electrophysiol Rev. 2021; (In press)
- Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.J Am Soc Echocardiogr. 2015; 28: 1-39
- Cardiac resynchronization in chronic heart failure.N Engl J Med. 2002; 346: 1845-1853
- Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.Circulation. 2012; 126: 822-829
- Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy.Circulation. 2010; 121: 626-634
- His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study.Circ Arrhythm Electrophysiol. 2019; 12e006934
- Cardiac resynchronization therapy with wireless left ventricular endocardial pacing: the SELECT-LV study.J Am Coll Cardiol. 2017; 69: 2119-2129
- Sequential His bundle and left ventricular pacing for cardiac resynchronization.J Cardiovasc Electrophysiol. 2020; 31: 2448-2454
- Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block.Europace. 2021; 21: 281-289
- Electrocardiographic patterns and long-term clinical outcome in cardiac resynchronization therapy.Europace. 2010; 12: 216-222
- QRS fusion complex analysis using wave interference to predict reverse remodeling during cardiac resynchronization therapy.Heart Rhythm. 2014; 11: 806-813
- Cardiac resynchronization therapy in patients with nonischemic cardiomyopathy using left bundle branch pacing.JACC Clin Electrophysiol. 2020; 6: 849-858
- Intracardiac delineation of septal conduction in left bundle branch block patterns: mechanistic evidence of left intra-hisian block circumvented by His pacing.Circulation. 2019; 139: 1876-1888
- Physiology-based electrocardiographic criteria for left bundle branch capture.Heart Rhythm. 2021; 18: 935-943
Funding Sources: None.
Disclosures: Drs Jastrzebski, Moskal, Huybrechts, and Curila have received consultant fees from Medtronic. Dr Herweg has received consultant fees from Abbott and Biotronik. Dr Sharma has received consultant fees from Abbott, Biotronik, Boston Scientific, and Medtronic. Dr Vijayaraman has received research and fellowship support as well as speaker and consultant fees from Medtronic. He has also received consultant fees from Abbott and Biotronik. The rest of the authors report no conflicts of interest.